Albert Bourla, Pfizer CEO (Michel Euler/AP Images, Pool)

FDA ap­proves Pfiz­er’s RSV shot for old­er adults, tee­ing up a com­pet­i­tive $17B vac­cine mar­ket

The FDA ap­proved Pfiz­er’s RSV vac­cine called Abrys­vo for old­er adults on Wednes­day, plac­ing an­oth­er Big Phar­ma on­to the com­mer­cial stage ahead of the next RSV sea­son.

Pfiz­er’s ap­proval comes weeks af­ter GSK won ap­proval for its ri­val shot, Arexvy. Those two vac­cines are both ap­proved for use in adults 60 years and old­er and will be re­viewed by a CDC pan­el in June be­fore they’re ex­pect­ed to com­mer­cial­ly launch this fall. Wall Street an­a­lysts see RSV as the next multi­bil­lion-dol­lar vac­cine mar­ket, with Jef­feries an­a­lysts re­cent­ly fore­cast­ing the RSV mar­ket will grow to $17 bil­lion over the next decade.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.